PMGC Holdings Inc. is a U.S.-based diversified holding company that owns and operates a portfolio of subsidiaries across biotechnology, scientific research, and specialized manufacturing. Its structure combines direct operating businesses with investment and acquisition activities through PMGC Capital LLC and other wholly owned subsidiaries.
31,4 %
−1 313,0 %
1.74
1.72
| % | |
|---|---|
| Investment and capital allocation | 35% Direct investments, strategic lending, and acquisition of undervalued assets and businesses. |
| Biotechnology and biosciences | 20% Development of aesthetic medicines and therapeutic products through NorthStrive BioSciences. |
| Scientific research and development | 10% Medical research activities and collaboration with Canadian universities through PMGC Research. |
| Precision manufacturing | 20% CNC machining and high-tolerance component production through AGA Precision Systems. |
| Packaging and related operating services | 15% IT packaging and related services provided by operating subsidiaries such as Pacific Sun Packaging. |
PMGC sells to a mix of business customers, research partners, and capital counterparties rather than a single end...
Buy CNC-machined and high-tolerance components for production and engineering applications.
Buy packaging-related services from operating subsidiaries for product handling and shipment needs.
Collaborate on scientific research and development, often supported by grants and partnerships.
Support development, validation, and future licensing of biosciences assets and technologies.
Provide or receive capital through investments, lending, acquisitions, and structured transactions.
PMGC is headquartered in the United States, but its operating footprint includes U.S.-based subsidiaries and a Canadian...
PMGC’s strategy is to build value through acquisitions, subsidiary formation, and commercialization of newly acquired...
The holding-company model depends on buying assets below intrinsic value and improving them through capital allocation.
Clinical validation and IND progress are needed to create licensing, partnership, or commercialization value.
Operating businesses diversify the portfolio and can provide recurring commercial activity outside of investment gains.
PMGC faces execution risk because its value creation depends on acquiring, integrating, and financing a diverse set of...
The business model relies on buying and managing multiple subsidiaries and assets, which can fail to create value if integration or underwriting is weak.
NorthStrive BioSciences depends on successful validation and IND progression before its assets can be commercialized or licensed.
Precision manufacturing and packaging subsidiaries may face customer concentration, demand swings, and execution constraints.
PMGC Research is Canadian-dollar functional, so translation can affect reported results and equity.
Investments, derivative liabilities, and stock-based awards require judgment and can create earnings volatility.
: 29.4.2026